Abbvie (ABBV) Management Makes A Case For No Generic Botox, Biz On Track - Cowen
Tweet Send to a Friend
Cowen analyst Steve Scala reiterated an Outperform rating and $90.00 price target on Abbvie (NYSE: ABBV) after meeting with management ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
